AccurKardia Revenue
Software Development • 
Manhattan, New York, United States • 11-20 Employees
AccurKardia revenue & valuation
| Annual revenue | $1,000,000 |
| Revenue per employee | $59,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Software Development industry and current estimated revenues | $3,200,000 |
| Total funding | $4,700,000 |
Key Contacts at AccurKardia
Juan C Jimenez
Co-Founder And Ceo
Tony Kuttiachen
Co-Founder
Company overview
| Headquarters | 101 Avenue of the Americas, New York, NY 10013, US |
| Website | |
| Keywords | Medical Devices, Biomarkers, Diagnostics, IoT, AI, Artificial Intelligence, ECG, Remote Patient Monitoring, Medtech, EKG, Aortic Stenosis, CKD, Biomarker, Healthtech, Esrd, Digitalhealth, Hyperkalemia, Cardiac Healthcare, Ecg Analysis |
| Founded | 2019 |
| Employees | 11-20 |
| Socials |
AccurKardia Email Formats
AccurKardia uses 4 email formats. The most common is {first initial}{last name} (e.g., jdoe@accurkardia.com), used 40% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@accurkardia.com | 40% |
{first name}{last name} | johndoe@accurkardia.com | 40% |
{first name} | john@accurkardia.com | 10% |
{last name}{first name} | doejohn@accurkardia.com | 10% |
About AccurKardia
AccurKardia is an ECG-led diagnostics software company transforming ECG data into a more powerful diagnostic tool and broad biomarker to improve patient outcomes and save lives globally. Its cloud-based platform includes AccurECG™, an FDA-cleared Class II software as a medical device (SaMD) that delivers fully automated, near real-time ECG interpretation and integrates seamlessly into existing clinical workflows. AccurECG™ was named “Best New ECG Technology” at the 2025 MedTech Breakthrough Awards. AccurKardia’s pipeline includes AK+ Guard™—an AI-driven hyperkalemia detection solution using Lead I ECG data to help identify life-threatening high potassium levels earlier in patients with CKD and ESRD—which received FDA Breakthrough Device Designation and acceptance into FDA’s Total Product Life Cycle (TAP) program in December 2024; and AK-AVS™, an AI model for aortic stenosis detection via 12-lead ECGs, which received FDA Breakthrough Device Designation in October 2024. AccurKardia completed the 2024 MedTech Innovator (MTI) cohort and was one of five companies selected for the American Heart Association’s inaugural Heart & Brain Health Accelerator track within MTI. AccurKardia also completed Cohort 3 of Mayo Clinic Platform_Accelerate in 2023. (AK+ Guard™ and AK-AVS™ are investigational and not commercially available.)
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
AccurKardia has 10 employees across 3 departments.
Departments
Number of employees
Funding Data
Explore AccurKardia's funding history, including investment rounds, total capital raised, and key backers.
AccurKardia Tech Stack
Discover the technologies and tools that power AccurKardia's digital infrastructure, from frameworks to analytics platforms.
Security
JavaScript frameworks
Hosting
Programming languages
Security
Miscellaneous
JavaScript frameworks
Miscellaneous
JavaScript libraries
PaaS
Bahrain
France
United Kingdom
South Africa
SpainFrequently asked questions
4.8
40,000 users
